Advertisement
Mayo Clinic Proceedings Home

Photodynamic Therapy for Early Stage Squamous Cell Carcinoma of the Lung

      Objective

      To study the effectiveness of photody-namic therapy (PDT) as a therapeutic strategy in roentgenographically occult squamous cell carcinoma of the lung.

      Material and Methods

      A carefully selected group of 21 patients (with 23 cancers) who had early stage squamous cell carcinoma of the lung and were eligible for surgical treatment were offered PDT as an alternative to resection. Patients underwent close follow-up with bronchoscopic surveillance and were offered resection if cancer persisted after no more than two sessions of PDT.

      Results

      A complete response was identified in 15 patients (16 cancers) after an initial PDT session. A complete response that lasted longer than 12 months was noted in 11 patients (52%). After PDT, the minimal follow-up period was 24 months. A subsequent primary lung cancer developed in 5 of the 21 patients (24%). Ten patients ultimately had surgical treatment, in 3 (30%) of whom Nl disease was identified at the time of resection. Two patients refused a surgical procedure and received alternative therapy. Therefore, nine patients (43%) were spared an operation (95% confidence interval, 21.8 to 66.6%). The mean duration of follow-up for these nine patients was 68 months (range, 24 to 116).

      Conclusion

      On the basis of this investigation, we can conclude with 95% confidence that at least 22% of patients with early stage squamous cell lung cancer who are candidates for PDT can be spared surgical resection.
      HpD (hematoporphyrin derivative), PDT (photodynamic therapy)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Parker SL
        • Tong T
        • Bolden S
        • Wingo PA
        Cancer statistics, 1996.
        CA Cancer J Clin. 1996; 46: 5-27
        • Gail MH
        • Eagan RT
        • Feld R
        • Ginsberg R
        • Goodell B
        • Hill L
        Prognostic factors in patients with resected stage I non-small cell lung cancer: a report from the Lung Cancer Study Group.
        Cancer. 1984; 54: 1802-1813
        • Pairolero PC
        • Williams DE
        • Bergstralh EJ
        • Piehler JM
        • Bernatz PE
        • Payne WS
        Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease.
        Ann Thorac Surg. 1984; 38: 331-338
        • Williams DE
        • Pairolero PC
        • Davis CS
        • Bernatz PE
        • Payne WS
        • Taylor WF
        Survival of patients surgically treated for stage I lung cancer.
        J Thorac Cardiovasc Surg. 1981; 82: 70-76
        • Cortese DA
        • Pairolero PC
        • Bergstralh EJ
        • Woolner LB
        • Uhlenhopp MA
        • Piehler JM
        Roentgenographically occult lung cancer: a ten-year experience.
        J Thorac Cardiovasc Surg. 1983; 86: 373-380
        • Hayata Y
        • Funatsu H
        • Kato H
        • Saito Y
        • Sawamura K
        • Furose K
        Results of lung cancer screening programs in Japan.
        Rec Results Cancer Res. 1982; 82: 163-173
        • Fontana RS
        • Sanderson DR
        • Woolner LB
        • Taylor WF
        • Miller WE
        • Muhm JR
        Lung cancer screening: the Mayo program.
        J Occup Med. 1986; 28: 746-750
        • Ball Jr, WC
        • Frost JK
        • Tockman MS
        • Levin M
        Screening for lung cancer: the effect of 5-7 years of periodic roentgeno-graphic and cytologic examinations on detection, survival and mortality from lung cancer [abstract].
        Am Rev Respir Dis. 1985; 131: A84
        • Errett LE
        • Wilson J
        • Chiu RC
        • Munro DD
        Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients.
        J Thorac Cardiovasc Surg. 1985; 90: 656-661
        • Little AG
        • DeMeester TR
        • Ferguson MK
        • Skinner DB
        • Hoffman PC
        • Skosey C
        Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrent patterns, and adjuvant immunotherapy.
        Surgery. 1986; 100: 621-628
        • Crabbe MM
        • Patrissi GA
        • Fontenelle LJ
        Minimal resection for bronchogenic carcinoma: an update.
        Chest. 1991; 99: 1421-1424
        • Iascone C
        • DeMeester TR
        • Albertucci M
        • Little AG
        • Golomb HM
        Local recurrence of resectable non-oat cell carcinoma of the lung: a warning against conservative treatment for N0 and N, disease.
        Cancer. 1986; 57: 471-476
        • Ginsberg RJ
        • Hill LD
        • Eagan RT
        • Thomas P
        • Mountain CF
        • Deslauriers J
        Modern thirty-day operative mortality for surgical resections in lung cancer.
        J Thorac Cardiovasc Surg. 1983; 86: 654-658
        • Cortese DA
        • Kinsey JH
        Endoscopic management of lung cancer with hematoporphyrin derivative phototherapy.
        Mayo Clin Proc. 1982; 57: 543-547
        • Cortese DA
        • Kinsey JH
        Hematoporphyrin derivative phototherapy in the treatment of bronchogenic carcinoma.
        Chest. 1984; 86: 8-13
        • Cortese DA
        Endobronchial management of lung cancer.
        Chest. 1986; 89: 234S-236S
        • Edell ES
        • Cortese DA
        Bronchoscopic phototherapy with hematoporphyrin derivative for treatment of localized bronchogenic carcinoma: a 5-year experience.
        Mayo Clin Proc. 1987; 62: 8-14
        • Edell ES
        • Cortese DA
        Bronchoscopic localization and treatment of occult lung cancer.
        Chest. 1989; 96: 919-921
        • Edell ES
        • Cortese DA
        Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection.
        Chest. 1992; 102: 1319-1322
        • Hayata Y
        • Kato H
        • Konaka C
        • Ono J
        • Takizawa N
        Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer.
        Chest. 1982; 81: 269-277
        • Hayata Y
        • Kato H
        • Konaka C
        • Amemiya R
        • Ono J
        • Ogawa I
        Photoradiation therapy with hematoporphyrin derivative in early and stage 1 lung cancer.
        Chest. 1984; 86: 169-177
        • Kato H
        • Konaka C
        • Ono J
        • Kawate N
        • Nishimiya K
        • Shinohara H
        Preoperative laser photodynamic therapy in combination with operation in lung cancer.
        J Thorac Cardiovasc Surg. 1985; 90: 420-429
        • Kato H
        • Konaka C
        • Kawate N
        • Shinohara H
        • Konoshita K
        • Noguchi M
        Five-year disease-free survival of a lung cancer patient treated only by photodynamic therapy.
        Chest. 1986; 90: 768-770
        • Kato H
        • Kawate N
        • Kinoshita K
        • Yamamoto H
        • Furukawa K
        • Hayata Y
        Photodynamic therapy of early-stage lung cancer.
        Ciba Found Symp. 1989; 146: 183-194
        • Sutedja T
        • Baas P
        • Stewart F
        • van Zandwijk N
        A pilot study of photodynamic therapy in patients with inoperable non-small cell lung cancer.
        Eur J Cancer. 1992; 28A: 1370-1373
        • Lipson RL
        • Baldes EJ
        • Olsen AM
        The use of a derivative of hematoporphyrin in tumor detection.
        J Natl Cancer Inst. 1961; 26: 1-11
        • Woolner LB
        • Fontana RS
        • Cortese DA
        • Sanderson DR
        • Bernatz PE
        • Payne WS
        Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period.
        Mayo Clin Proc. 1984; 59: 453-466
        • Ono R
        • Ikeda S
        • Suemasu K
        Hematoporphyrin derivative photodynamic therapy in roentgenographically occult carcinoma of the tracheobronchial tree.
        Cancer. 1992; 69: 1696-1701
        • Furuse K
        • Fukuoka M
        • Kato H
        • Horai T
        • Kubota K
        • Kodama N
        A prospective phase II study on photodynamic therapy with Photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.
        J Clin Oncol. 1993; 11: 1852-1857
        • Sutedja T
        • Lam S
        • LeRiche JC
        • Postmus PE
        Response and pattern of failure after photodynamic therapy for intraluminal stage I lung cancer.
        J Bronchol. 1994; 1: 295-298
        • Slaughter DP
        • Southwick HW
        • Smejkal W
        “Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin.
        Cancer. 1953; 6: 963-968
        • Christensen PH
        • Joergensen K
        • Munk J
        • Oesterlind A
        Hyperfrequency of pulmonary cancer in a population of 415 patients treated for laryngeal cancer.
        Laryngoscope. 1987; 97: 612-614
        • van Velzen E
        • Snijder RJ
        • de la Rivière AB
        • Elbers HJJ
        • van den Bosch JMM
        Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma: lymph node involvement by direct extension compared with lobar and hilar node metastases.
        Chest. 1996; 110: 1469-1473
        • Mao L
        • Hruban RH
        • Boyle JO
        • Tockman M
        • Sidransky D
        Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.
        Cancer Res. 1994; 54: 1634-1637

      Linked Article